TransMedics Group, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $190.3M | $35.5M | $-25.0M | $-36.2M | $-44.2M | $-28.7M | $-33.5M | $-23.8M |
| Depreciation & Amortization | $27.2M | $19.8M | $8.2M | $3.5M | $1.8M | $1.6M | $1.2M | $769.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | $200.0K | $200.0K | $100.0K | — | — | — | — | — |
| Stock-Based Compensation | $36.9M | $33.2M | $19.8M | $10.3M | $6.9M | $2.4M | $854.0K | $144.0K |
| Net Cash from Operating Activities | $192.8M | $48.8M | $-13.0M | $-45.8M | $-28.9M | $-30.3M | $-32.3M | $-26.0M |
| Investing Activities | ||||||||
| Capital Expenditures | $59.3M | $129.7M | $151.8M | $11.9M | $3.5M | $455.0K | $165.0K | $418.0K |
| Business Acquisitions | — | — | $14.9M | — | — | — | — | — |
| Net Cash from Investing Activities | $-59.3M | $-129.3M | $-194.0M | $54.5M | $29.3M | $-41.6M | $-60.5M | $12.3M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $16.9M | $22.9M | $400.4M | $167.9M | $1.4M | $75.5M | $92.7M | $22.1M |
| Net Change in Cash | $151.7M | $-58.2M | $193.6M | $175.6M | $999.0K | $4.5M | $-149.0K | $8.3M |
| Free Cash Flow | $133.6M | $-80.9M | $-164.9M | $-57.7M | $-32.4M | $-30.7M | $-32.5M | $-26.4M |